国内英语新闻:China invests 4 bln yuan in ITER project in decade
BEIJING, Nov. 28 (Xinhua) -- China has invested four billion yuan (about 600 million U.S. dollars) in the International Thermonuclear Experimental Reactor (ITER) project in the past 10 years, the Ministry of Science and Technology (MST) announced Tuesday.
The largest international scientific cooperation project in the world, the ITER is a France-based international nuclear fusion research and engineering project that explores commercial uses of fusion power.
It is jointly funded by China, the EU, India, Japan, Republic of Korea, Russia and the United States.
"Since 2008, China has carried out nearly 120 fusion power projects and has made leading achievements," said Luo Delong from the MST.
Chinese scientists set a record by achieving 101.2 seconds of steady-state H-mode operation of the tokamak in July, an experimental device designed to harness the energy of fusion.
China's Experimental Advanced Superconducting Tokamak (EAST) -- the "artificial sun" -- was the first tokamak device to break the 100-second barrier.
According to the ITER's plan, the construction of the "artificial sun" will be completed by 2025, and the commercial uses of fusion power is expected to be available around 2050, said Pan Chuanhong from the MST.
相关文章
- 英语文摘:China urges G7 to cease interfering in its internal affairs
- 英语文摘:HKSAR gov't strongly refutes G7, EU statements on chief executive election
- 英语文摘:Xi's keynote speech at opening ceremony of Boao Forum for Asia Annual Conference 2022 publ
- 英语文摘:Xi attends ceremony marking centenary of Communist Youth League of China
- 英语文摘:Xi talks with Macron over phone
- 英语文摘:External interference in Hong Kong affairs doomed to be self-defeating: Commissioner's off
- 英语文摘:Chinese spokesperson slams Western countries smearing Hong Kong election
- 英语文摘:China calls for equal, balanced global development partnership
- 英语文摘:Xinhua Headlines: A look at younger generation on China's new journey
- 英语文摘:Chinese vice premier reiterates dynamic zero-COVID policy